BioNTech SE (BNTX) Stock

BioNTech SE, headquartered in Mainz, Germany, is a leading biotechnology company focused on the development and commercialization of innovative immunotherapies for cancer and infectious diseases. Founded in 2008, BioNTech is at the forefront of mRNA-based therapies, pioneering a range of product candidates designed to address unmet medical needs across various oncology indications and infectious diseases. The company's pipeline includes FixVac product candidates like BNT111 for advanced melanoma, BNT112 for prostate cancer, BNT113 for HPV+ head and neck cancers, BNT114 for triple negative breast cancer, BNT115 for ovarian cancer, and BNT116 for non-small cell lung cancer, all progressing through clinical trials.

In addition to its FixVac platform, BioNTech is advancing neoantigen specific immunotherapies such as Autogene cevumeran (BNT122) for melanoma and multiple solid tumors, and mRNA intratumoral immunotherapy like SAR441000 for solid tumors. The company also focuses on developing chimeric antigen receptor T cell (CAR-T) therapies, including BNT211 for multiple solid tumors and BNT221 for other cancers, along with checkpoint immunomodulators GEN1046 and GEN1042 for solid tumors. Further expanding its portfolio, BioNTech is developing BNT321, a monoclonal antibody for pancreatic cancer, BNT411, a small molecule immunomodulator for solid tumors, and prophylactic vaccines for COVID-19 and influenza.

BioNTech collaborates with a diverse range of partners including Genentech, Inc., Sanofi S.A., Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Regeneron Pharmaceuticals, Inc., and Ryvu Therapeutics S.A. These collaborations underscore BioNTech's commitment to advancing innovative therapies through strategic partnerships and cutting-edge research, aiming to transform the treatment landscape for cancer and infectious diseases globaly.